Our commitment to corporate governance underpins the trust that our investors, employees and institutions have in us. We maintain our efforts to build confidence as we continue to grow.
Valneva’s Management Board is a highly dedicated international team, with diverse backgrounds, experience, expertise and skills.
CEO of Intercell since 2011, Managing Director for Novartis Vaccines & Diagnostics Germany, Vice President of Global Industrial Operations at Chiron Vaccines, more than 25 years in the vaccine industry.
CEO and co-founder of Vivalis since 1999, formerly responsible for Groupe Grimaud’s development in Asia, 25 years in corporate business development and life sciences.
CFO of vaccine biotech company Acambis, Vice President Finance, Business Development and Strategy at Chiron Vaccines, Vice President Finance GSK, non-executive and advisory experience, 30 years of experience in vaccines and life sciences.
Senior international positions at various large life science companies including Novartis, Takeda, Pfizer and Hoechst, experiences in scientific-medical affairs, drug development and general management of vaccines and pharmaceuticals, more than 30 years of experience in life sciences.
As part of Valneva’s corporate governance system, the Supervisory Board, acting in the interests of the shareholders, participates actively in reviewing the Company’s strategic options and setting direction together with the Management Board.
Chairman of Valneva’s Supervisory Board, Representative of the Company's largest shareholder, President and CEO of Groupe Grimaud.
Vice-Chairperson of the Supervisory Board & Chair - Nomination & Compensation Committee, Vice President Medical Affairs at The Medicines Company, Former Vice President Marketing at Merck & Co.
Member of the Supervisory Board & Chair - Audit Committee, Former CFO for Chiron and CEO of Maxygen.
Member of the Supervisory Board, Managing Director of SMAG Consulting, Supervisory Board member of Nanobiotix SA, Board member of Sartorius Stedim Biotech SA, Former Vice President at Sanofi Pasteur MSD.
Member of the Supervisory Board, Chairman of the trans-European innovation consortium EITHealth, Former Vice-President of the Karolinska Institute, Co-founder of Intercell.
Member of the Supervisory Board, Partner at MVM Partners LLP, Qualified as chartered accountant with PWC’s Private Equity and Venture Capital practice. Board member of eZono AG, Onbone Oy and Patient Connect Ltd.
Scientific Advisory Board
Valneva announced the formation of a Scientific Advisory Board (SAB) as part of the evolution of its governance structure in July 2019.
Member of Board of Trustees International Vaccine Institute IVI, member GHIT scientific selection committee, Advisor Bill & Melinda Gates Foundation, former Head/Senior Vice President Vaccine Development at GSK, Novartis and Takeda
President and CEO of Biologics Consulting, Temporary Advisor to the World Health Organization; Former Director of the US FDA Office of Vaccines Research and Review; Former FDA Liaison to the Centers for Disease Control’s Advisory Committee on Immunization Practices
Professor of International Health at the Johns Hopkins Bloomberg School of Public Health, Principal Investigator at the Center for Immunization Research
Board member of Amryt Pharma, Supervisory Board member of OxThera AB, Zealand Pharma A/S, former SVP for international development at Sanofi, former SVP of the pharmaceutical division at Fournier Laboratories
Adjunct Professor of Medicine at Johns Hopkins University, Co-founder and Board Member of Affinivax, Board Member of Genocea, former Supervisory Board Member of Crucell and former Executive Vice President and CSO of Wyeth Vaccines
Emeritus Professor, Wistar Institute, University of Pennsylvania, Former director of the division of infectious diseases at Children’s Hospital of Philadelphia, associate Chairman of the department of pediatrics at the University of Pennsylvania and Medical Director at Sanofi Pasteur